| abstract |
The present invention provides biomarker proteins whose concentration or activity level changes correlate with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with complement inhibitors. The present invention also provides compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in biological fluids. Among other things, the compositions and methods are useful for assessing the risk of developing aHUS, diagnosing aHUS, determining whether a subject is experiencing a first exacerbation of aHUS, monitoring the progression or elimination of aHUS, and/or monitoring the use of Response to, or optimization of, treatment with a complement inhibitor would be useful. |